Rec'd PCT/PTO 03 AUG 2005

SEQUENCE LISTING

```
<110> Stangl, Verena
       Stangl, Karl
       Lorenz, Mario
      Use of a Proteosome Inhibitor in the Treatment of Endothelial
<120>
       Dysfunction and/or in a Low-Dose Proteosome Inhibitor Therapy
<130>
      2958-128
<140> 10/522,706
<141> 2005-01-28
<150> PCT/EP03/08495
<151> 2003-07-31
<150> EP 02 017 234.2
<151> 2002-07-31
<160>
     17
<170> PatentIn version 3.3
<210> 1
<211> 4
<212> PRT
<213> Artificial
<220>
<223> synthetic proteosome inhibitor with binding affinity for human
       proteins involved in eNOS regulation
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> modified with carbobenzoxy group
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> modified with OBut or OtBu group
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> modified with H or CHO
<400> 1
Ile Gly Ala Leu
```

```
<210> 2
<211> 4
<212> PRT
<213> Artificial
<220>
      synthetic proteosome inhibitor with binding affinity for human
<223>
      proteins involved in eNOS regulation
<220>
<221>
     MISC FEATURE
<222>
      (4) ...(4)
      modified with vinylsulfone group
<223>
<400>
Tyr Leu Leu Leu
<210>
      3
<211> 4
<212> PRT
<213> Artificial
<220>
<223> synthetic proteosome inhibitor with binding affinity for human
      proteins involved in eNOS regulation
<220>
<221> MISC_FEATURE
<222>
      (1)..(1)
<223> modified with adamantaneacetyl group
<220>
<221> MISC FEATURE
<222> (2)..(2)
<223> modified with 3 (6-aminohexanoyl) groups
<220>
<221> MISC FEATURE
<222>
      (4)..(4)
<223> modified with vinylsulfone group
<400> 3
Tyr Leu Leu Leu
<210> 4
<211> 4
<212> PRT
```

```
<213> Artificial
<220>
<223> synthetic proteosome inhibitor with binding affinity for human
      proteins involved in eNOS regulation
<220>
<221> MISC_FEATURE
<222>
      (1)..(1)
<223> modified with adamantaneacetyl group
<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> biotinylated
<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> modified with 3 (6-aminohexanoyl) groups
<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> modified with vinylsulfone group
<400> 4
Lys Leu Leu Leu
1
<210> 5
<211> 4
<212> PRT
<213> Artificial
<220>
<223> synthetic proteosome inhibitor with binding affinity for human
      proteins involved in eNOS regulation
<220>
<221> MISC FEATURE
<222>
      (1)..(1)
<223> modified with acetylmethyl group
<220>
      MISC_FEATURE
<221>
<222>
      (4)..(4)
<223> modified with epoxomicin
```

1

<400> 5

	Ile Ile 1	Thr Leu	
	<211> <212>	6 21 DNA Homo sapiens	
		6 cca ggaagaagac c	21
	<211> <212>	7 19 DNA Homo sapiens	
		7 gct tcgccatca	19
	<211> <212>	8 29 DNA Homo sapiens	
		8 gtg gccaacgccg tgaagatct	29
	<211> <212>	9 25 DNA Homo sapiens	
		9 ctt atatccaaca cttcg	25
	<211> <212>	10 22 DNA Homo sapiens	÷
		10 ctt tccttggtca gg	22
	<211> <212>	11 26 DNA Homo sapiens	
,	<400>	11	

tttcaccagc		cagc	aagcttgcga	ccttga	26
<2 <2	210> 211> 212> 213>	12 28 DNA Bos	taurus		
	100>	12	gagactggac	cagaagtt	28
L (Lacca	ıcaa	gagaccggac	cagaagee	20
<2 <2	210> 211> 212> 213>	13 22 DNA Bos	taurus		
	100>	13			22
at	tgaca	agca	ctggcttagg	ca	22
<2 <2	210> 211> 212> 213>		taurus		
	400>	14		ababb	25
gc	ctataa	agtt	ctttgccgac	ctgtt	23
<2 <2	210> 211> 212> 213>	15 26 DNA Bos	taurus		-
	100>	15			2.0
tt	cctgtt	cag	tgctttgatg	taatcc	26
<2 <2	210> 211> 212> 213>	16 22 DNA Bos	taurus		
	400>	16	L L		22
aç	gtaget	ggt	tccctccgaa	gı	22
<2 <2	210> 211> 212> 213>	17 19 DNA Bos	taurus		
	400>	17	gccagctat		19
(- u - u a l	,	g o o a g o c a c		